Serum activity of prolyl endopeptidase, but not of dipeptidyl peptidase IV, is decreased by immunotherapy with IFN-α in high-risk melanoma patients

Journal of Interferon and Cytokine Research

Volumn 24, Issue 7, 2004, Pages 411-415

  Van Gool, A R ^a   Van Ojik, H H ^a   Kruit, W H J ^a   Mulder, P G H ^a   Fekkes, D ^a   Bannink, M ^a   Scharpe S ^b   Stoter, G ^a   Eggermont, A M M ^a   Maes, M ^c   Verkerk, R ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; DIPEPTIDYL PEPTIDASE IV; PROLYL ENDOPEPTIDASE;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DISEASE EXACERBATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; MALE; MELANOMA; PRIORITY JOURNAL; SIDE EFFECT;

ANTIGENS, CD26; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPATITIS; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; MALE; MELANOMA; MOOD DISORDERS; SERINE ENDOPEPTIDASES;

EID: 3242891144     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/1079990041535629     Document Type: Article

References (38)

1. DIEPERINK, E., WILLENBRING, M., and HO, S.B. (2000). Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am. J. Psychiatry 157, 867-876.
2. TRASK, P.C., ESPER, P., RIBA, M., and REDMAN, B. (2000). Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J. Clin. Oncol. 18, 2316-2326.
3. VAN GOOL, A.R., KRUIT, W.H.J., ENGELS, F.K., STOTER, G., BANNINK, M., and EGGERMONT, A.M.M. (2003). Neuropsychiatric side effects of interferon-alfa therapy. Pharm. World Sci. 25, 11-20.
4. KRONFOL, Z., and REMICK, D.G. (2000). Cytokines and the brain: implications for psychiatry. Am. J. Psychiatry 157, 683-694.
5. KONSMAN, J.P., LUHESHI, G.N., BLUTHE, R.M., and DANTZER, R. (2000). The vagus nerve mediates behavioural depression, but not fever, in response to peripheral immune signals: a functional anatomical analysis. Eur. J. Neurosci. 12, 4434-4446.
6. WICHERS, M.C., and MAES, M. (2002). Mechanisms of interferon-alpha- induced depressive symptoms. Acta Neuropsychiatrica 14, 103-105.
7. HOPSU-HAVU, V.K., and GLENNER, G.G. (1966). A new dipeptide naphtylamidase hydrolyzing glycyl-propyl-β-naphtylamide. Histochemistry 7, 197-201.
8. GOOSSENS, F., DE MEESTER, I., VANHOOF, G., and SCHARPÉ, S. (1996). Distribution of prolyl endopeptidase in human peripheral tissues and body fluids. Eur. J. Clin. Chem. Clin. Biochem. 34, 17-22.
9. CAMARGO, A.C., CALDO, H., and EMSON, P.C. (1983). Degradation of neurotensin by rabbit brain endo-oligopeptidase A and endo-oligopeptidase B (proline endopeptidase). Biochem. Biophys. Res. Commun. 116, 1151-1159.
10. LOPEZ-JARAMILLO, P., ANTUNES-RODRIGUES, J., and CAMARGO, A.C. (1984). Effects of gonadal steroids on hypothalamus and anterior pituitary endo-oligopeptidase B (proline-endopeptidase) activity in castrated female rats. Peptides 5, 1017-1019.
11. WARD, P.E., BAUSBACK, H.H., and ODYA, C.C. (1987). Kinin and angiotensin metabolism by purified renal post-proline cleaving enzyme. Biochem. Pharmacol. 36, 3187-3193.
12. WELCHES, W.R., BROSNIHAN, K.B., and FERRARIO, C.M. (1993). A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. Life Sci. 52, 1461-1480.
13. NAGAOKA, I., and YAMASHITA, T. (1985). Possible involvement of aminopeptidase, an ecto-enzyme, in the inactivation of bradykinin by intact neutrophils. Biochim. Biophys. Acta 847, 67-76.
14. MAES, M., GOOSSENS, F., SCHARPÉ, S., MELTZER, H.Y., D'HONDT, P., and COSYNS, P. (1994). Lower serum prolyl endopeptidase activity in major depression: further evidence that peptides play a role in the pathophysiology of depression. Biol. Psychiatry 35, 545-552.
15. MAES, M., AI-HUA, L., BONACCORSO, S., GOOSSENS, F., VAN GASTEL, A., PIOLO, R., DELMEIRE, L., and SCHARPÉ, S. (1999). Higher serum prolyl endopeptidase activity in patients with post-traumatic stress disorder. J. Affect. Disord. 53, 27-34.
16. MAES, M., GOOSSENS, F., SCHARPÉ, S., CALABRESE, J., DESNYDER, R., and MELTZER, H.Y. (1995). Alterations in plasma prolyl endopeptidase activity in depression, mania and schizophrenia: effects of antidepressants, mood stabilizers, and antipsychotic drugs. Psychiatry Res. 58, 217-225.
17. MAES, M., LIBBRECHT, I., VAN HUNSEL, F., LIN, A.H., BONACCORSO, S., GOOSSENS, F., DE MEESTER, I., DE CLERCK, L., BIONDI, M., SCHARPÉ, S., and JANCA, A. (1998). Lower serum activity of prolyl endopeptidase in fibromyalgia is related to severity of depressive symptoms and pressure hyperalgesia. Psychol. Med. 28, 957-965.
18. MAES, M., MONTELEONE, P., BENCIVENGA, R., GOOSSENS, F., MAJ, M., VAN WEST, D., BOSMANS, E., and SCHARPÉ, S. (2001). Lower serum activity of prolyl endopeptidase in anorexia and bulimia nervosa. Psychoneuroendocrinology 26, 17-26.
19. WILLIAMS, R.S.B., EAMES, M., RYVES, W.J., VIGGARS, J., and HARWOOD, A.J. (1999). Loss of a prolyl oligopeptidase confers resistance to lithium by elevation of inositol (1,4,5) triphosphate. EMBO J. 18, 2734-2745.
20. WILLIAMS, R.S.B., CHENG, L., MUDGE, A.W., and HARWOOD, A.J. (2002). A common mechanism of action for three mood-stabilizing drugs. Nature 417, 292-295.
21. DURINX, C., LAMBEIR, A.M., BOSMANS, E., FALMAGNE, J.B., BERGHMANS, R., HAEMERS, A., SCHARPÉ, S., and DE MEESTER, I. (2000). Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur. J. Biochem. 267, 5608-5613.
22. MAES, M., BONACCORSO, S., MARINO, V., PUZELLA, A., PASQUINI, M., BIONDI, M., ARTINI, M., ALMERIGHI, C., and MELTZER, M. (2001). Treatment with interferon-alpha (IFN-α) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN-α-induced depressive and anxiety symptoms and immune activation. Mol. Psychiatry 6, 475-480.
23. LAMBEIR, A.-M., DURINX, C., SCHARPÉ, S., and DE MEESTER, I. (2003). Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DDPIV. Crit. Rev. Clin. Lab. Sci. 40, 209-294.
24. MAES, M., DE MEESTER, I., VANHOOF, G., SCHARPÉ, S., BOSMANS, E., VANDERVORST, C., VERKERK, R., MINNER, B., SUY, E., and RAUS, J. (1991). Decreased serum dipeptidyl peptidase IV activity in major depression. Biol. Psychiatry 30, 577-586.
25. MAES, M., DE MEESTER, I, SCHARPÉ, S., DESNYDER, R., RANJAN, R., and MELTZER, M. (1996). Alterations in plasma dipeptidyl peptidase IV enzyme activity in depression and schizophrenia: effects of antidepressants and antipsychotic drugs. Acta Psychiatr. Scand. 93, 1-8.
26. MAES, M., DE MEESTER, I., VERKERK R., DE MEDTS, P., WAUTERS, A., VANHOOF, G., VANDOOLAEGHE, E., NEELS, H., and SCHARPÉ, S. (1997). Lower serum dipeptidyl peptidase IV activity in treatment resistant major depression: relationships with immune-inflammatory markers. Psychoneuroendocrinology 22, 65-78.
27. VAN WEST, D., MONTELEONE P., DI LIETO, A., DE MEESTER, I., DURINX, C., SCHARPÉ S., LIN, A., MAJ, M., and MAES, M. (2000). Lower serum activity of dipeptidyl peptidase IV in patients with anorexia and bulimia nervosa. Eur. Arch. Psychiatry Clin. Neurosci. 250, 86-92.
28. HILDEBRANDT, M., ROSE, M., MONNIKES, H., REUTTER, W., KELLER, W., and KLAPP, B.F. (2001). Eating disorders: a role for dipeptidyl peptidase IV in nutritional control. Nutrition 17, 451-454.
29. MAES, M., CAPURON, L., RAVAUD, A., GUALDE, N., BOSMANS, E., EGYED, B., and DANTZER, R. (2001). Lowered serum dipeptidyl peptidase IV activity is associated with depressive symptoms and cytokine production in cancer patients receiving interleukin-2-based immunotherapy. Neuropsychopharmacology 24, 130-140.
30. VAN GOOL, A.R., FEKKES, D., KRUIT, W.H.J., MULDER, P.G.H., TEN HAGEN, T.L.M., BANNINK, M., MAES, M., and EGGERMONT, A.M.M. (2003). Serum amino acids, biopterin and neopterin during long-term immunotherapy with interferon-alpha in high risk melanoma patients. Psychiatry Res. 119, 125-132.
31. GOOSSENS, F., DE MEESTER, I., VANHOOF, G., and SCHARPÉ, S. (1992). A sensitive method for the assay of serum prolyl endopeptidase. Eur. J. Clin. Chem. Clin. Biochem. 30, 235-238.
32. DURINX, C., NEELS, H., VAN DER AUWERA, J.-C., NAELAERTS, K., SCHARPÉ, S., and DE MEESTER, I. (2001). Reference values for plasma dipeptidyl peptidase activity and their association with other laboratory parameters. Clin. Chem. Lab. Med. 39, 155-159.
33. HUENGSBERG, M., WINER, J.B., GOMPELS, M., ROUND, R., ROSS, J., and SHAHMANESH, M. (1998). Serum kynurenine-to-tryptophan ratio increases with progressive disease in HIV-infected patients. Clin. Chem. 44, 858-862.
34. FEKKES, D., VAN DALEN, A., EDELMAN, M., and VOSKUILEN, A.J. (1995). Validation of the determination of amino acids in plasma by high-performance liquid chromatography using automated derivatization with o-phthaldialdehyde. J. Chromatogr. B. Biomed. Appl. 669, 177-186.
35. HOEKSTRA, R., VAN DEN BROEK, W.W., FEKKES, D., BRUIJN, J.A., MULDER, P.G.M., and PEPPLINKHUIZEN, L. (2001). Effect of electroconvulsive therapy on biopterin and large neutral amino acids in severe medication-resistant depression. Psychiatry Res. 103, 115-123.
36. LIBERATI, A.M., HORISBERGER, M.A., GAROFANI, P., DE ANGELIS, V., FERRAJOLI, A., DI CLEMENTE, F., CARICCHI, P., ADIUTO, D., FEDELI, L., and PALUMBO, B. (1994). Interferon-α-induced biological modifications in patients with chronic myelogenous leukemia. J. Interferon Res. 14, 349-355.
37. BONACCORSO, S., MARINO, V., PUZELLA, A., PASQUINI, M., BIONDI, M., ARTINI, M., ALMERIGHI, C., VERKERK, R., MELTZER, H., and MAES, M. (2002). Increased depressive ratings in patients with hepatitis C receiving interferon-α-based immunotherapy are related to interferon-α-induced changes in the serotonergic system. J. Clin. Psychopharmacol. 22, 86-90.
38. CAPURON, L., RAVAUD, A., NEVEU, P.J., MILLER, A.H., MAES, M., and DANTZER, R. (2002). Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol. Psychiatry 7, 468-473.